Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts By Watertime - March 12, 2026 7 Post Content RELATED ARTICLESMORE FROM AUTHOR Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM Psychedelic Philanthropy Is Entering Its Next Phase Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD
